Literature DB >> 8369643

Human brain fluoxetine concentrations.

C N Karson1, J E Newton, R Livingston, J B Jolly, T B Cooper, J Sprigg, R A Komoroski.   

Abstract

Data on 22 subjects treated with fluoxetine suggest that magnetic resonance spectroscopy (MRS) of fluorine-19 can measure brain concentrations of fluoxetine/norfluoxetine in vivo. Fluoxetine accumulates in the human brain relative to plasma, with brain concentrations of fluoxetine/norfluoxetine ranging up to 10.7 micrograms/ml. Brain concentrations may reach a plateau between 6 and 8 months of treatment. The apparent concentration in brain relative to plasma is 20:1, roughly parallel to brain antidepressant concentration ratios in animal studies.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8369643     DOI： 10.1176/jnp.5.3.322

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN： 0895-0172            Impact factor:   2.198


  50 in total

Review 1.  Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice.

Authors:  M J Burke; S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

2.  Toward 19F magnetic resonance thermometry: spin-lattice and spin-spin-relaxation times and temperature dependence of fluorinated drugs at 9.4 T.

Authors:  Christian Prinz; Paula Ramos Delgado; Thomas Wilhelm Eigentler; Ludger Starke; Thoralf Niendorf; Sonia Waiczies
Journal:  MAGMA       Date:  2018-12-04       Impact factor: 2.310

3.  Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse.

Authors:  Alex G Nackenoff; Alexandra B Moussa-Tooks; Austin M McMeekin; Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2015-10-30       Impact factor: 7.853

4.  Inhibition of G protein-activated inwardly rectifying K+ channels by fluoxetine (Prozac).

Authors:  Toru Kobayashi; Kazuo Washiyama; Kazutaka Ikeda
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

5.  Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor.

Authors:  E P Pälvimäki; B L Roth; H Majasuo; A Laakso; M Kuoppamäki; E Syvälahti; J Hietala
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

6.  Antidepressants inhibit Nav1.3, Nav1.7, and Nav1.8 neuronal voltage-gated sodium channels more potently than Nav1.2 and Nav1.6 channels expressed in Xenopus oocytes.

Authors:  Takafumi Horishita; Nobuyuki Yanagihara; Susumu Ueno; Dan Okura; Reiko Horishita; Tomoko Minami; Yuichi Ogata; Yuka Sudo; Yasuhito Uezono; Takeyoshi Sata; Takashi Kawasaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-09-14       Impact factor: 3.000

7.  Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution.

Authors:  Johannes Kornhuber; Jens Wiltfang; Peter Riederer; Stefan Bleich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

8.  Tricyclic antidepressant imipramine reduces the insulin secretory rate in islet cells of Wistar albino rats through a calcium antagonistic action.

Authors:  M-H Antoine; D Gall; S N Schiffmann; P Lebrun
Journal:  Diabetologia       Date:  2004-04-16       Impact factor: 10.122

9.  Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes.

Authors:  János Magyar; Norbert Szentandrássy; Tamás Bányász; Valéria Kecskeméti; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-26       Impact factor: 3.000

10.  The antidepressant fluoxetine mobilizes vesicles to the recycling pool of rat hippocampal synapses during high activity.

Authors:  Jasmin Jung; Kristina Loy; Eva-Maria Schilling; Mareike Röther; Jan M Brauner; Tobias Huth; Ursula Schlötzer-Schrehardt; Christian Alzheimer; Johannes Kornhuber; Oliver Welzel; Teja W Groemer
Journal:  Mol Neurobiol       Date:  2013-11-05       Impact factor: 5.590
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.